MS patients more compliant with medications when managed by specialty pharmacy

...ogram, according to a study completed by HealthCore, Inc. HealthCore researcher Jingbo Yu presented the study today at the International Society of pharmacoeconomic and Outcomes Research 14th Annual International Meeting in Orlando, Fla. The retrospective study analyzed medical and pharmacy claims data. The He...

New Study Reveals Wide Variations in Depression Diagnoses among Ethnic Groups

... than other ethnic groups, according to a new Consumer Health Sciences (CHS) study presented today at the 14th Annual ISPOR (International Society for pharmacoeconomic and Outcomes Research) Conference in Orlando, Florida. The study reveals that 76% of whites with self-reported depression symptoms are officially diag...

MS Patients More Compliant with Medications When Managed by Specialty Pharmacy, According to HealthCore Study Presented at ISPOR

...ram, according to a study completed by HealthCore, Inc. HealthCore researcher Jingbo Yu presented the study today at the International Society of pharmacoeconomic and Outcomes Research 14th Annual International Meeting in Orlando, Fla. The retrospective study analyzed medical and pharmacy claims data. The ...

Personalized Medicine Makes Significant Headway Following the Rapid Evolution of U.S. Molecular Diagnostics Market, Finds Frost & Sullivan

... of the test in the market. In order to interact smoothly with reimbursement agencies and convince them, U.S. CMD companies must accomplish insightful pharmacoeconomic analysis to display the value proposition of CMD. U.S. Cancer Molecular Diagnostics Markets is part of the Drug Discovery and Clinical Diagnos...

Clinical pharmacists can reduce drug costs

...s, reductions in adverse drug events and medication errors and other savings, says Glen Schumock, associate professor and director of UIC's Center for pharmacoeconomic Research and senior researcher on the study. Schumock and his colleagues evaluated 93 studies published between 2001 and 2005 to uncover the impact...

Partnership for Safe Medicines Arms Public Against Counterfeit Drugs

... About Marvin D. Shepherd, Ph.D. In addition to serving as the president of the Partnership, Dr. Marv Shepherd is the director of the Center for pharmacoeconomic Studies; and chairman of the Pharmacy Administration Division at the University of Texas at Austin's College of Pharmacy. Among his many research i...

NovoLogix Launches First Annual Symposium for Healthcare Thought Leaders

...nitiatives, including mandates from the Centers for Medicare and Medicaid Services (CMS), innovations in e-prescribing, electronic health records, and pharmacoeconomic measurements "NovoLogix is proud to be sponsoring this one-of-a-kind event and providing an opportunity for some of the very best minds in the field...

Also in the Oct. 28 JNCI

...als or bone marrow transplantation, which is the only curative therapy available. "These data may be useful for estimating the resource utility and pharmacoeconomic impact of MDS in the United States," the authors conclude. Contact: Megan Ferington Pruce, prucem@ccf.org , (216) 445-7452 or (216) 312-3602 (cell...

Hepatitis C treatment is cost-effective for the US prison population

...fective approach, however, as one could potentially exclude certain patients with no fibrosis from therapy." "If the decision to treat is based on pharmacoeconomic measures," the authors conclude, "the results of our analysis suggest that treatment is cost-saving and should not be withheld in U.S. prisoners with ...

Majority of House of Representatives Support Common-Sense Fix to Medicare Part D Prescription Drug Plan

... and Charles Grassley (R-Iowa). Further evidence that H.R. 1474 is a much-needed bill can be found in the University of Texas at Austin's Center for pharmacoeconomic Studies report called the "Length of Prescription Drug Payment Times by Medicare Part D Plans." Click here to learn more: http://www.ncpanet.org/pdf/...

Pharmacoeconomic in Medical Technology

First Pharmacoeconomic Analysis with Long-Term Data Showed Copaxone Was More Cost-Effective Than Interferon Beta Therapies for Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)

KANSAS CITY, Mo.--(BUSINESS WIRE)--Apr 11, 2007 - A comparison of the long-term economic outcomes of four immunomodulatory drug therapies combined with symptom management versus symptom management alone revealed that COPAXONE(R) (glatiramer acetate injection) was the most cost-effective treatment s...

New One-Year Pharmacoeconomic Study Shows Avonex is Cost-Effective Relative to Other Interferon Therapies for Multiple Sclerosis

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 13, 2007 - Biogen Idec Inc. (NASDAQ: BIIB) announced today that one-year data presented at the Academy of Managed Care Pharmacy's (AMCP) 2007 Annual Meeting show that AVONEX(R) (Interferon beta-1a) is a cost-effective therapy in multiple sclerosis (MS) when co...

Targanta Initiates Phase 2 Oritavancin Infrequent Dosing Study

...nd Chief Executive Officer of Targanta, commented on the study: "If successful, we believe a less frequent dosing regimen for oritavancin could confer pharmacoeconomic benefits through shorter hospital stays and reduced use of hospital resources. In addition, our market research has indicated that simplified dosing r...

Pharmacoeconomic in Biological Technology

Double Helix Strengthens its Strategic Pricing and Reimbursement Practice with Hire of Caryn Zieses

...sage development and testing Commercial assessment Development program and clinical trial planning Managed markets strategy pharmacoeconomic evaluation and health technology assessment Payer and provider insight evaluation and influence planning Pricing and reimbursement strat...

Understanding Managed Markets: Effective Market Research Structures & Activities to Maximize Payer Access & Insights

...ring Phase 3, though most benchmark partners are moving to push these into earlier phases. This may prove most viable for breakthrough medicines where pharmacoeconomic differences can be identified, and may prove less effective for me-too drugs, as pushing research earlier may give payers more time to develop strateg...

Studies Presented at International Conference on Alzheimer's Disease Reveal Substantial Economic Costs and Caregiver Burden Associated with Alzheimer's Disease

...asing dependence. In this study, dependence level provided a useful method to estimate unique levels of care and associated costs that can be used in pharmacoeconomic evaluations of new treatments for AD patients in a transparent and meaningful manner. Poster #P1-180: Relationship Between Patient Depen...

Double Helix Appoints Ann Stuchiner Vice President of US Consulting Division

...development and testing Commercial assessment Development program and clinical trial planning Managed markets strategy pharmacoeconomic evaluation and health technology assessment Payer and provider insight evaluation and influence planning Pricing and reimbursement str...

London-Based Double Helix Consulting Launches US Division for Strategic Pricing, Reimbursement and Market Access Solutions

... Commercial assessment Lifecycle planning Development program and clinical trial planning Managed markets strategy pharmacoeconomic evaluation and health technology assessment (HTA) Payer and provider insight evaluation and influence planning Pricing and reimburseme...

ACORN Expands Oncology Information Portfolio With Comprehensive Data Warehouse

... and full complement of reliable data sets that are assessed and analyzed by our experienced scientific team." ACORN's unique data warehouse enables pharmacoeconomic and health outcomes analysis previously unachievable. "In addition to traditional sources of information, we have a unique component in our PACE PRO g...

Rosetta Genomics Reports Fourth-Quarter and Full-Year 2007 Financial Results

...on. Second, they are designed to assist clinicians in determining the most appropriate treatment for patients. Third, the tests are backed by a strong pharmacoeconomic rationale. "We are constantly expanding our diagnostic pipeline, both through collaborations as well as internally, with tests aimed to fulfill these ...

Targanta Submits Oritavancin New Drug Application

...t, we believe oritavancin may become part of a new treatment paradigm for infections caused by MRSA and other gram-positive bacteria, and could confer pharmacoeconomic benefits, if approved." "Despite the introduction of several new antibiotics in the past decade, we continue to see an increase in the development o...

On track with the FDA -- But what about your coverage and reimbursement strategy?

...reatment Planning clinical trials to capture the data needed for coverage and reimbursement decisions, such as studies that have both clinical and pharmacoeconomic endpoints (i.e., comparisons to existing technologies or treatments) Early planning is essential to help ensure that the product will be covered a...